论文部分内容阅读
目的:检测并分析弥漫大B细胞淋巴瘤(DLBCL)患者石蜡样本中的miR-224的表达水平,并探讨其在预后评估中的意义。方法:回顾性分析我院有详细随访资料的DLBCL患者的石蜡样本84例,以8例反应性增生的淋巴结作为对照,采用TaqMan探针实时定量PCR的方法检测其miR-224的表达水平,并探讨其表达水平与临床数据及预后的关系。结果:miR-224在DLBCL患者组的表达水平为(0.98±0.24),而对照组的表达水平为(1.87±0.17),差异有统计学意义(P<0.01)。miR-224表达水平与患者的性别、年龄、乳酸脱氢酶水平及Hans分型无相关性(均P>0.05),而患者的Ann Arbor分期及IPI评分与miR-224表达水平具有相关性(均P<0.05)。以miR-224表达水平的中位数为阈值将84例DLBCL患者分为高表达组和低表达组,miR-224高表达组的无复发生存期及总生存期均高于低表达组,差异有统计学意义(P<0.05)。多因素Cox分析显示,IPI评分≥3分(P=0.030)及miR-224低表达(P=0.038)均为独立的预后不良因素。结论:miR-224在DLBCL患者石蜡样本中低表达,可能作为抑癌基因参与DLBCL的发生发展,其表达水平与免疫亚型无关,高表达组的5年无复发生存期和总生存期均高于低表达组,提示miR-224可作为一个新的DLBCL预后判断标志物。
OBJECTIVE: To detect and analyze the expression of miR-224 in paraffin-embedded samples from patients with diffuse large B-cell lymphoma (DLBCL) and to explore its significance in prognosis evaluation. Methods: A retrospective analysis of our hospital with detailed follow-up data of DLBCL patients with paraffin specimens of 84 cases, 8 cases of reactive hyperplasia lymph nodes as a control, real-time quantitative PCR using TaqMan probe to detect miR-224 expression levels and To investigate the relationship between the expression level and clinical data and prognosis. Results: The expression level of miR-224 in patients with DLBCL was (0.98 ± 0.24) vs. (1.87 ± 0.17), the difference was statistically significant (P <0.01). There was no correlation between the expression level of miR-224 and the gender, age, lactate dehydrogenase level and Hans type (all P> 0.05), while the Ann Arbor stage and IPI score were correlated with the expression of miR-224 All P <0.05). 84 patients with DLBCL were divided into high expression group and low expression group with the median of miR-224 as the threshold value. The recurrence-free survival and overall survival of miR-224 overexpression group were higher than those in low expression group There was statistical significance (P <0.05). Multivariate Cox analysis showed that IPI scores ≥3 (P = 0.030) and miR-224 low (P = 0.038) were independent prognostic factors. CONCLUSIONS: miR-224 is low expressed in paraffin-embedded samples of DLBCL patients and may participate in the development of DLBCL as a tumor suppressor gene. The expression level of miR-224 is independent of immune subtype. The 5-year recurrence-free survival and overall survival of high- Low expression group, suggesting that miR-224 can be used as a new DLBCL prognostic marker.